Ranirestat
- Generic Name
- Ranirestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11BrFN3O4
- CAS Number
- 147254-64-6
- Unique Ingredient Identifier
- Z26P56GFTV
- Background
Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
- Indication
Investigated for use/treatment in neuropathy (diabetic).
- Associated Conditions
- -
- Associated Therapies
- -
Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT00927914
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath